CN103168037A - 激酶抑制剂的合成和用途 - Google Patents
激酶抑制剂的合成和用途 Download PDFInfo
- Publication number
- CN103168037A CN103168037A CN2011800421749A CN201180042174A CN103168037A CN 103168037 A CN103168037 A CN 103168037A CN 2011800421749 A CN2011800421749 A CN 2011800421749A CN 201180042174 A CN201180042174 A CN 201180042174A CN 103168037 A CN103168037 A CN 103168037A
- Authority
- CN
- China
- Prior art keywords
- compound
- formula
- solution
- approximately
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CCCC(N(C*)CCOCCC)=CC(OC)=C(C=C*)NC1=CC(NC(C=CC(C)(*)C=C2)=C2C(N*)=O)=C(C(F)(F)F)C(C)(*)C=N1 Chemical compound CCCC(N(C*)CCOCCC)=CC(OC)=C(C=C*)NC1=CC(NC(C=CC(C)(*)C=C2)=C2C(N*)=O)=C(C(F)(F)F)C(C)(*)C=N1 0.000 description 5
- IGUBBWJDMLCRIK-UHFFFAOYSA-N CNC(c1ccccc1Nc1cc(Nc(ccc(N2CCOCC2)c2)c2OC)ncc1C(F)(F)F)=O Chemical compound CNC(c1ccccc1Nc1cc(Nc(ccc(N2CCOCC2)c2)c2OC)ncc1C(F)(F)F)=O IGUBBWJDMLCRIK-UHFFFAOYSA-N 0.000 description 2
- DZADIHSSWKMGIZ-UHFFFAOYSA-N CNC(c1cc(F)ccc1Nc1cc(Nc(ccc(N2CCOCC2)c2)c2OC)ncc1C(F)(F)F)=O Chemical compound CNC(c1cc(F)ccc1Nc1cc(Nc(ccc(N2CCOCC2)c2)c2OC)ncc1C(F)(F)F)=O DZADIHSSWKMGIZ-UHFFFAOYSA-N 0.000 description 1
- BQTMHUUWYHEPNQ-UHFFFAOYSA-N COc(cc(cc1)N2CCOCC2)c1N Chemical compound COc(cc(cc1)N2CCOCC2)c1N BQTMHUUWYHEPNQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
Description
时间 | Cs2CO3(%产率) | K2CO3(%产率) | K2CO3水溶液(%产率) |
3小时 | 96.5 | 14 | 24 |
18小时 | 100 | 61.4 | 49 |
42小时 | N/A | 92 | 60 |
66小时 | N/A | 100 | 69 |
序号 | SM-1:Pd催化剂比例 | 反应时间(小时) | 产率(%) | SM-1(%) | 杂质*(%) |
1a | 2mol% | 4 | 96 | 2.6 | 0.9 |
2a | 1mol% | 4 | 81 | 36 | 0.7 |
3a | 0.5mol% | 4 | 63 | 36 | 0.7 |
4a | 0.1mol% | 4 | 6** | 94** | 0 |
5a | 0.05mol% | 4 | 10 | 90 | 0 |
1b | 2mol% | 18 | 88 | 0 | 12 |
2b | 1mol% | 18 | 95 | 0 | 5 |
3b | 0.5mol% | 18 | 97 | 0 | 3 |
4b | 0.1mol% | 18 | 17** | 83** | 3 |
5b | 0.05mol% | 18 | 87 | 0 | 12 |
序号 | SM-1:Pd催化剂比例 | 反应时间(小时) | 产率(%) | SM-1(%) | 杂质*(%) |
1a | 0.50mol% | 14 | 96.47 | 2.58 | 0.94 |
2a | 0.25mol% | 14 | 95.46 | 4.54 | N/A |
3a | 0.10mol% | 14 | 84.69 | 15.3 | N/A |
1b | 0.50mol% | 24 | 98.77 | 0 | 1.22 |
2b | 0.25mol% | 24 | 98.12 | 1.88 | N/A |
3b | 0.10mol% | 24 | 91.67 | 8.33 | N/A |
Claims (48)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35994210P | 2010-06-30 | 2010-06-30 | |
US61/359,942 | 2010-06-30 | ||
PCT/US2011/042169 WO2012012139A1 (en) | 2010-06-30 | 2011-06-28 | Synthesis and use of kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
CN103168037A true CN103168037A (zh) | 2013-06-19 |
Family
ID=45497129
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2011800421749A Pending CN103168037A (zh) | 2010-06-30 | 2011-06-28 | 激酶抑制剂的合成和用途 |
Country Status (10)
Country | Link |
---|---|
US (1) | US9505719B2 (zh) |
EP (1) | EP2588476A4 (zh) |
JP (1) | JP5923499B2 (zh) |
CN (1) | CN103168037A (zh) |
AU (1) | AU2011280031B2 (zh) |
CA (1) | CA2803005A1 (zh) |
MX (1) | MX343894B (zh) |
NZ (1) | NZ604801A (zh) |
WO (1) | WO2012012139A1 (zh) |
ZA (1) | ZA201300012B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103534240B (zh) | 2011-02-17 | 2015-12-09 | 癌症疗法Crc私人有限公司 | 选择性fak抑制剂 |
EP2675793B1 (en) | 2011-02-17 | 2018-08-08 | Cancer Therapeutics Crc Pty Limited | Fak inhibitors |
WO2019117813A1 (en) * | 2017-12-15 | 2019-06-20 | National University Of Singapore | Focal adhesion kinase targeted therapeutics for the treatment of glaucoma and fibrosis |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4656182A (en) * | 1983-12-06 | 1987-04-07 | Warner-Lambert Company | Substituted trans-1,2-diaminocyclohexyl amide compounds |
WO2004002410A2 (en) * | 2002-06-27 | 2004-01-08 | Bristol-Myers Squibb Company | 2,4-disubstituted-pyridine n-oxides useful as hiv reverse transcriptase inhibitors |
CN101495095A (zh) * | 2006-04-28 | 2009-07-29 | 先灵公司 | 通过受控的沉淀来沉淀和分离6,6-二甲基-3-氮杂-双环[3.1.0]己烷-酰胺化合物的方法和含有其的药学制剂 |
CN101679264A (zh) * | 2007-03-16 | 2010-03-24 | 斯克里普斯研究学院 | 粘着斑激酶抑制剂 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040006005A1 (en) | 2002-07-02 | 2004-01-08 | Sanjay Bhanot | Use of integrin-linked kinase inhibitors for treating insulin resistance, hyperglycemia and diabetes |
GB9828511D0 (en) | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
GB0004887D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
ATE417608T1 (de) | 2000-10-11 | 2009-01-15 | Cephalon Inc | Arzneizusammensetzungen enthaltend modafinilverbindungen |
US20080119515A1 (en) | 2003-03-10 | 2008-05-22 | M Arshad Siddiqui | Heterocyclic Kinase Inhibitors: Methods of Use and Synthesis |
GT200500310A (es) | 2004-11-19 | 2006-06-19 | Compuestos organicos | |
CN101119976B (zh) | 2005-02-18 | 2010-12-22 | 泰博特克药品有限公司 | 抑制hiv的2-(4-氰基苯氨基)嘧啶氧化物衍生物 |
CA2626579A1 (en) | 2005-10-25 | 2007-05-03 | Abbott Laboratories | Formulation comprising a drug of low water solubility and method of use thereof |
EP2012753A2 (en) * | 2006-04-28 | 2009-01-14 | Schering Corporation | Process for the precipitation and isolation of 6,6-dimethyl-3-aza-bicyclo [3.1.0]hexane-amide compounds by controlled precipitation and pharmaceutical formulations containing same |
DK2046292T3 (da) | 2006-07-21 | 2010-06-07 | Novartis Ag | Formuleringer for benzimidazolylpyridylethere |
WO2009100176A2 (en) | 2008-02-07 | 2009-08-13 | Abbott Laboratories | Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor |
WO2009105498A1 (en) * | 2008-02-19 | 2009-08-27 | Smithkline Beecham Corporation | Anilinopyridines as inhibitors of fak |
US8569298B2 (en) * | 2008-06-17 | 2013-10-29 | Astrazeneca Ab | Pyridine compounds |
CN102648197A (zh) | 2009-08-12 | 2012-08-22 | 铂雅制药公司 | 促进细胞凋亡和抑制转移的方法 |
WO2011133668A2 (en) | 2010-04-20 | 2011-10-27 | President And Fellows Of Harvard College | Methods and compositions for the treatment of cancer |
-
2011
- 2011-06-28 WO PCT/US2011/042169 patent/WO2012012139A1/en active Application Filing
- 2011-06-28 NZ NZ60480111A patent/NZ604801A/en not_active IP Right Cessation
- 2011-06-28 AU AU2011280031A patent/AU2011280031B2/en not_active Ceased
- 2011-06-28 MX MX2012014986A patent/MX343894B/es active IP Right Grant
- 2011-06-28 JP JP2013518575A patent/JP5923499B2/ja not_active Expired - Fee Related
- 2011-06-28 CA CA2803005A patent/CA2803005A1/en not_active Abandoned
- 2011-06-28 CN CN2011800421749A patent/CN103168037A/zh active Pending
- 2011-06-28 EP EP11810100.5A patent/EP2588476A4/en not_active Withdrawn
-
2013
- 2013-01-02 ZA ZA2013/00012A patent/ZA201300012B/en unknown
- 2013-08-07 US US13/961,517 patent/US9505719B2/en not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4656182A (en) * | 1983-12-06 | 1987-04-07 | Warner-Lambert Company | Substituted trans-1,2-diaminocyclohexyl amide compounds |
WO2004002410A2 (en) * | 2002-06-27 | 2004-01-08 | Bristol-Myers Squibb Company | 2,4-disubstituted-pyridine n-oxides useful as hiv reverse transcriptase inhibitors |
CN101495095A (zh) * | 2006-04-28 | 2009-07-29 | 先灵公司 | 通过受控的沉淀来沉淀和分离6,6-二甲基-3-氮杂-双环[3.1.0]己烷-酰胺化合物的方法和含有其的药学制剂 |
CN101679264A (zh) * | 2007-03-16 | 2010-03-24 | 斯克里普斯研究学院 | 粘着斑激酶抑制剂 |
Also Published As
Publication number | Publication date |
---|---|
MX343894B (es) | 2016-11-28 |
MX2012014986A (es) | 2013-07-03 |
JP2013529687A (ja) | 2013-07-22 |
AU2011280031B2 (en) | 2015-09-10 |
EP2588476A1 (en) | 2013-05-08 |
AU2011280031A1 (en) | 2013-01-10 |
EP2588476A4 (en) | 2014-07-23 |
US20140235635A1 (en) | 2014-08-21 |
CA2803005A1 (en) | 2012-01-26 |
WO2012012139A1 (en) | 2012-01-26 |
JP5923499B2 (ja) | 2016-05-24 |
ZA201300012B (en) | 2013-09-25 |
NZ604801A (en) | 2015-03-27 |
US9505719B2 (en) | 2016-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1257264A (en) | Imidazoheterocyclic compounds and processes for preparation thereof | |
JPH0216315B2 (zh) | ||
CN102712637A (zh) | 制备{4,6-二氨基-2-[1-(2-氟苄基)-1H-吡唑并[3,4-b]吡啶-3-基]嘧啶-5-基}氨基甲酸甲酯的方法以及其用作医药活性物质的纯化 | |
CN101085775A (zh) | 培美曲塞中间体及制备方法 | |
CN101146809A (zh) | 制备喹啉化合物的方法和由其获得的产物 | |
CN103168037A (zh) | 激酶抑制剂的合成和用途 | |
CN1090620C (zh) | 新的苯并咪唑,苯并唑和苯并噻唑化合物,制备它们的方法和含有它们的药物组合物 | |
CN100402515C (zh) | 用作抗惊厥药的取代2-苯并[c]呋喃酮 | |
EP2882753A1 (en) | Process for the preparation of pemetrexed and lysin salt thereof | |
JPS61210085A (ja) | 免疫調節剤として有効なイミダゾ〔4,5−f〕キノリン | |
CN102924350B (zh) | 截短侧耳素衍生物及其制备方法和应用 | |
HU180240B (en) | Process for producing new,substituted 1,3-diaryl-2-iminoimidasolidines and 2-imino-hexahydro-pyrimidines | |
WO2000062782A1 (en) | Novel synthesis and crystallization of piperazine ring-containing compounds | |
US6355651B1 (en) | Certain pyrrolopyridine derivatives; novel CRF1 specific ligands | |
CN114085213B (zh) | 一种arv-471的制备方法 | |
RU2300532C2 (ru) | Производные бензо[g]хинолина для лечения глаукомы и близорукости, способ их получения и фармацевтическая композиция | |
US20030069417A1 (en) | Novel synthesis and crystallization of piperazine ring-containing compounds | |
AU704115B2 (en) | Zwitterionic forms of trovafloxacin | |
JPS5843987A (ja) | 新規なジメチルホスホルアミデ−ト化合物 | |
GB2211187A (en) | Tromethamine salt of 1-methyl-¼-oxo-alpha-(phenylcarbamoyl)-2-pyrrolepropio- nitrile | |
DE1793050B2 (de) | Substituierte cyclische und acyclische Amidine sowie Mittel zur Bekämpfung der HelmintMasis, die diese Verbindungen enthalten | |
EP0154173B1 (en) | Pteridine derivatives, an anticancer composition containing same and a process for the production of said derivatives | |
CN101955472B (zh) | 马来酸桂哌齐特的制备方法 | |
US20030135043A1 (en) | Novel synthesis and crystallization of piperazine ring-containing compounds | |
KR100490970B1 (ko) | 신규 피리도[2,3-d]피리미딘 카르보알데히드 옥심계PDE Ⅳ 효소 저해 화합물 및 이의 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: VERASTEM INC. Free format text: FORMER OWNER: ENKATA CO., LTD. Effective date: 20140423 Owner name: ENKATA CO., LTD. Free format text: FORMER OWNER: PONIARD PHARMACEUTICALS INC. Effective date: 20140423 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20140423 Address after: Massachusetts, USA Applicant after: VERASTEM, Inc. Address before: California, USA Applicant before: The grace of the Limited by Share Ltd. Effective date of registration: 20140423 Address after: California, USA Applicant after: The grace of the Limited by Share Ltd. Address before: Washington State Applicant before: Boniad Pharmaceutical Co.,Ltd. |
|
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20130619 |
|
RJ01 | Rejection of invention patent application after publication |